Glucagon-like peptide 1 (GLP-1).
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing GLP-1 physiology and pharmacology without systematic search methodology or original human data.
PubMed 31767182 · doi:10.1016/j.molmet.2019.09.010
What was done
This paper presents a narrative overview of the physiological functions, pharmacology, and therapeutic potential of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists across metabolic and related conditions.
What was found
The abstract reports no quantitative data or numerical effect sizes. It describes GLP-1 as a pleiotropic hormone that stimulates glucose-dependent insulin secretion, slows gastric emptying, inhibits food intake, increases natriuresis/diuresis, and modulates rodent beta-cell proliferation. It also notes cardioprotective, neuroprotective, anti-inflammatory, and anti-apoptotic actions, alongside effects on learning, memory, reward behavior, and palatability. Modified GLP-1 receptor agonists are noted as clinically established for type 2 diabetes and under clinical evaluation for obesity.
Why it matters
It highlights GLP-1 as a multi-system regulator whose therapeutic scope extends beyond glycemic control in diabetes to obesity and potential neurodegenerative disease management.
Limits
The abstract provides no original empirical data, sample sizes, or quantitative outcome metrics. As a narrative review, it lacks formal systematic search criteria, risk-of-bias evaluation, and meta-analytic synthesis. Several cited biological actions (such as beta-cell proliferation) are explicitly derived from rodent models and may not fully translate to humans.
Cited by
- contradicts Arne Astrup has published multiple human studies demonstrating that GLP-1 does not stimulate insulin secretion or act as an insulin secretagogue in humans.